INTERPATH-001

1. 05:03
   ESMO 2026 现场信号

   INTerpath-001: personalized mRNA therapy meets its primary RFS endpoint in resected stage IIB–IV melanoma.
2. 04:00
   ESMO 2026 现场信号

   "OS is pending, but the adjuvant melanoma bar just moved." — @shilpaonc
3. 02:50
   ESMO 2026 现场信号

   💯% agree Huge logistics and potential #GlobalOnc disparities for the deployment of a personalized adjuvant mRNA vaccine (intismeran autogene) INTerpath-001 trial
4. 02:16
   ESMO 2026 现场信号

   🧬 #ESMO26 | INTerpath-001: ¿nuevo paradigma en melanoma resecado?
5. 01:40
   ESMO 2026 现场信号

   Promising data from #ESMO26 Presidential Symposium I: INTerpath-001 showed a 42% reduction in recurrence or death with individualized mRNA neoantigen therapy + pembrolizumab vs pem
6. 01:18
   ESMO 2026 现场信号

   INTerpath-001: In macroscopic stage III melanoma, added value beyond neoadjuvant IO remains unclear. Next: target patients without MPR—but can vaccines overcome IO resistance? Valu
7. 01:00
   STAT News精选

   ESMO 2026公布intismeran INTerpath-001结果，黑色素瘤复发风险降低42%

   ESMO 2026公布intismeran INTerpath-001结果，黑色素瘤复发风险降低42%，无远处转移生存期相关风险降低38%。同场DeLLphi-305中，563例广泛期小细胞肺癌患者接受Imdelltra联合Imfinzi后死亡风险降低58%，中位OS略高于21个月而Imfinzi单药组不足13个月，近半出现CRS且多数为轻中度。

8. 00:57
   ESMO 2026 现场信号

   #ESMO26 PS I wrap-up, 4 LBAs, all positive:
9. 00:54
   ESMO 2026 现场信号

   🚨 #ESMO26 | INTerpath-001: Personalized mRNA neoantigen vaccine (intismeran) + pembrolizumab vs placebo + pembrolizumab in resected stage IIB–IV melanoma 💉
10. 00:37
    ESMO 2026 现场信号

    Personalized cancer vaccines are becoming a clinical reality! 🧬
11. 00:30
    ESMO 2026 现场信号

    Full INTerpath-001 data at ESMO 2026 detail OS, subgroup, and safety results with intismeran plus pembrolizumab in resected stage IIB to IV melanoma. #melanoma #ESMO26 | @myESMO @P
12. 00:10
    ESMO 2026 现场信号

    About the intismeran presentation at #ESMO26 $MRNA $MRK
13. 00:09
    ESMO 2026 现场信号

    #ScienceLink #Madrid2026 #ESMO26 #INTerpath001 #Melanoma
14. 00:07
    ESMO 2026 现场信号

    What a remarkable day at #ESMO26 in Madrid!
15. 00:07
    ESMO 2026 现场信号

    🚨 A personalized cancer vaccine just delivered Phase III success!

1. 23:56
   ESMO 2026 现场信号

   Sesión plenaria de #ESMO26. INTerpath-001: resultados fase III.
2. 23:47
   ESMO 2026 现场信号

   Historic at #ESMO26 Madrid - For the first time, an mRNA vaccine (intisimeran/mRNA-4157) given in the adjuvant setting shows positive results.
3. 23:30
   ESMO 2026 现场信号

   🧬 Personalized mRNA vaccines work‼️
4. 23:04
   ESMO 2026 现场信号

   Georgina Long presented INTerpath-001 at #ESMO26: intismeran + pembrolizumab vs placebo + pembrolizumab as adjuvant therapy for resected melanoma. It met the primary RFS endpoint (
5. 23:04
   ESMO 2026 现场信号

   🧬 Phase III INTerpath-001: Adjuvant intismeran + pembrolizumab improved RFS vs pembrolizumab + placebo in resected stage IIB–IV melanoma.
6. 23:01
   ESMO 2026 现场信号

   #Esmo26 discussant Inge Marie Svane on Interpath-001 vs neoadjuvant Opdivo + Yervoy (Nadina study) $MRNA $MRK
7. 23:01
   ESMO 2026 现场信号

   #ESMO26
8. 22:59
   ESMO 2026 现场信号

   INTerpath-001 raises exciting questions:
9. 22:56
   ESMO 2026 现场信号

   #ESMO26 | LBA1 – INTerpath-001
10. 22:56
    ESMO 2026 现场信号

    A milestone for personalized cancer vaccines.
11. 22:55
    ESMO 2026 现场信号

    In INTerpath-001, the combination of adjuvant Intismeran plus pembro is superior to pembro alone in resected melanoma mproves RFS in ITT 70% vs 82.2% HR 0.58 #ESMO2026 @darioT_ @my
12. 22:55
    ESMO 2026 现场信号

    Phase 3 results from the INTerpath-001 trial confirm that the individualized mRNA vaccine plus pembrolizumab significantly improves outcomes in adjuvant treatment of malignant mela
13. 22:53
    ESMO 2026 现场信号

    Presidential symposium
14. 22:52
    ESMO 2026 现场信号

    🔥 Presidential Symposium I #ESMO26
15. 22:52
    ESMO 2026 现场信号

    Practice-changing at #ESMO26 Presidential @ProfGLongMIA
16. 22:50
    ESMO 2026 现场信号

    🔥 #ESMO26 INTerpath-001, full data (now yes)
17. 22:50
    ESMO 2026 现场信号

    A question for the INTerpath-001 panel:
18. 22:49
    ESMO 2026 现场信号

    Impressive Phase III INTerpath-001 data at #ESMO26!
19. 22:49
    ESMO 2026 现场信号

    Presidential symposium 1️⃣!!
20. 22:49
    ESMO 2026 现场信号

    A long-awaited breakthrough in cancer vaccines.
21. 22:48
    ESMO 2026 现场信号

    #ESMO26 | INTerpath-001👇
22. 22:48
    ESMO 2026 现场信号

    🔥 Personalized cancer vaccines delivering impressive results at #ESMO26! @ProfGLongMIA
23. 22:48
    ESMO 2026 现场信号

    Superb presentation by Georgina Long! INTerpath-001: adding personalized mRNA vaccine intismeran to pembrolizumab reduced recurrence/death risk by 42% in resected stage IIB-IV mela
24. 22:40
    ESMO 2026 现场信号

    Ad #ESMO26 presentati i dati dello studio di Fase III INTerpath-001, che confermano l'efficacia di un vaccino terapeutico a mRNA per i pazienti con #melanoma ad alto rischio operat
25. 22:40
    ESMO 2026 现场信号

    #melanoma ad alto rischio: per la prima volta un #vaccino terapeutico dimostra la sua efficacia.
26. 22:30
    ESMO 2026 现场信号

    #ESMO26: Intismeran autogene individualised #mRNA-based #NeoantigenVaccine therapy reduced recurrence risk by 42% in patients with resectable #melanoma treated with adjuvant pembro
27. 21:39
    ESMO 2026 现场信号

    #ESMO26 | INTerpath-001: My Personal Perspective Ahead of the Presidential Session
28. 19:52
    ESMO 2026 现场信号

    OncoAlert 4Sight Abstracts to be Presented at #ESMO26
29. 19:25
    ESMO 2026 现场信号

    Does $MRNA $MRK Interpath-001 get the standing ovation at today's #ESMO26 presidential?
30. 18:03
    ESMO 2026 现场信号

    Today is the day at #ESMO26!
31. 14:48
    ESMO 2026 现场信号

    Twelve more patients in a hundred stay recurrence-free at 2 years — on top of pembrolizumab alone. INTerpath-001 (LBA1, #ESMO26): resected stage IIB–IV melanoma; intismeran autogen
32. 04:41
    ESMO 2026 现场信号

    #Madrid #ESMO26 | Main findings from INTerpath-001 released: #Intismeran + #pembrolizumab reduced risk of recurrence or death by 42% (HR, 0.58), risk of distant metastasis or death
33. 01:09
    ESMO 2026 现场信号

    Arriving at #ESMO26 tomorrow just in time for what promises to be one of the most exciting sessions: Presidential Session #1. #INTerpath-001 presented by @ProfGLongMIA, #VOLGA by @

1. 22:07
   ESMO 2026 现场信号

   @tonichoueiri with med onc pearls for neoantigen mRNA vaccines. The future is happening now — esp w readout of INTERPATH-001 trial this #ESMO26 @myESMO @oncoalert
2. 19:59
   中文产业新闻

   INTerpath-001三期结果阳性，BNT113联合帕博利珠单抗未改善PFS，mRNA肿瘤疫苗临床结果分化

   mRNA肿瘤疫苗临床结果出现分化，INTerpath-001三期结果阳性，而BNT113联合帕博利珠单抗一线治疗未显著改善PFS。

3. 19:30
   ESMO 2026 现场信号

   🔥 Melanoma: INTerpath-001 embargo lifts early at ESMO26: RFS HR 0.58, DMFS HR 0.62 (LBA1 abstract)
4. 18:12
   ESMO 2026 现场信号

   The embargo broke before #ESMO26 even opened.
5. 18:01
   ESMO 2026 现场信号

   Cancer vaccines take center stage at #ESMO26
6. 16:58
   ESMO 2026 现场信号

   Interested in context to interpret INTerpath-001 at #ESMO26?
7. 13:35
   ESMO 2026 现场信号

   🚨 Scientific embargoes exist for a reason: fair access to data, scientific integrity and, ultimately, patients.
8. 13:17
   ESMO 2026 现场信号

   🚨 #ESMO26 | Phase III INTerpath-001 🚨
9. 07:02
   ESMO 2026 现场信号

   @A_May_MD @deathtouch2k Same HR, different trials. S1801: phase 2, n=313, clinically detectable III–IV, EFS. INTerpath-001: phase 3, n=1137, resected IIB–IV incl. node-negative IIB
10. 05:59
    ESMO 2026 现场信号

    Adding Merck/Moderna’s individualized mRNA therapy intismeran to pembrolizumab cut the risk of recurrence or death by 42% in resected stage IIB-IV melanoma, per full phase 3 INTerp
11. 05:10
    ESMO 2026 现场信号

    Looking forward to the presentation and discussion. #LBA1 Phase 3 INTerpath-001 trial results at #ESMO26 👉🏽The Kaplan-Meir curves don’t always tell the whole story. Side effects, …
12. 05:04
    BioSpace

    INTerpath-001三期黑色素瘤数据提前外泄，intismeran autogene联合Keytruda的RFS HR为0.58

    INTerpath-001三期黑色素瘤数据在ESMO 2026前意外外泄，intismeran autogene联合Keytruda达到主要终点，RFS HR为0.58，对应复发或死亡风险降低42%。

13. 05:00
    ESMO 2026 现场信号

    🤷🏽‍♀️Proof that the market is irrational.
14. 04:52
    ESMO 2026 现场信号

    Long awaited results from INTerpath-001, the first Phase 3 trial to demonstrate efficacy of a personalized mRNA therapy!
15. 04:05
    ESMO 2026 现场信号

    @OncoAlert @brunolarvol @adamfeuerstein
16. 03:14
    ESMO 2026 现场信号

    INTerpath-001 leaked early. @myESMO lifted the embargo. RFS HR 0.58; Moderna −25%.
17. 03:05
    ESMO 2026 现场信号

    #ESMO26 embargo lifted following breach.
18. 02:46
    ESMO 2026 现场信号

    🚨 #ESMO26 INTerpath-001 leaked before the embargo, so @myESMO released it early
19. 02:40
    中文产业新闻精选

    INTerpath-001数据疑似提前泄露，Moderna股价暴跌

    INTerpath-001详细数据疑似在ESMO2026发布前泄露并引发疗效质疑，Moderna股价暴跌。原文称，中位随访24.6个月后，在帕博利珠单抗基础上加入intismeran可降低复发或死亡风险，HR=0.58。2年时，联合治疗组存活且无复发比例为82.2%，帕博利珠单抗单药组为70.0%。

20. 02:11
    ESMO 2026 现场信号

    #ESMO26: The embargo on LBA1, “INTerpath-001: Phase 3 study of the mRNA-based individualised neoantigen therapy intismeran autogene plus pembrolizumab versus pembrolizumab alone fo

1. 19:04
   ESMO 2026 现场信号

   What to watch at #ESMO26 in melanoma and skin cancers 👇 INTerpath-001 (LBA1), STARBOARD, HBI-8000-303, TIL, NADINA, C-POST, ADMEC-O, MATISSE 2. Plus ADCs after anti-PD-1, HER3-DX…
2. 13:52
   ESMO 2026 现场信号

   Five Phase 3 Trials to Watch at ESMO 2026 Positive toplines are in for INTerpath-001, VOLGA, DeLLphi-305, KRAScendo 1 and SAFFRON. Madrid must now show the effect sizes: HRs, abso…

1. 03:05
   社区讨论（Reddit）

   ESMO 2026 年会：15 项可能改变治疗实践的试验前瞻

   Reddit 用户整理了 ESMO 2026 年会（10-23 至 27 日，马德里）15 项可能改变治疗实践的试验前瞻清单。其中 INTerpath-001（intismeran autogene 联合帕博利珠单抗，高危黑色素瘤辅助治疗）三期无复发生存主要终点已于 2026-08 宣告阳性，完整数据将于 10-24 总统研讨会公布。会议尚未开幕，具体疗效数据仍待现场披露。

1. 17:26
   ESMO 2026 现场信号

   🚨 Excited to join the #ESMO26 @OncoAlert PULSE Faculty for melanoma & early drug development! 💥 My 10 trials to watch (pic 👇🏼) INTerpath-001 || MOIO || DeLLphi-305 || HARMONi-GI…

当前热度 315·可比范围峰值 376（10月25日 03:00）·近 24 小时可比范围变化 +302%·当前参与者 53

上图是参与者计数，下图是热度。趋势仅比较持续完整观测到的相同主体，范围可能小于当前热度统计。移动指针或点击图表查看每小时读数；键盘可用左右方向键切换。